News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Redsense Medical announces company has begun trading on the OTCQX under ticker 'RDSMF'

Redsense Medical

Redsense Medical CEO Pontus Nobreus joined Steve Darling from Proactive to share significant updates regarding the company's innovative Redsense System. This system plays a crucial role in monitoring and alerting healthcare providers in cases of blood leakage during hemodialysis treatments, addressing one of the most serious safety concerns in this medical field. The Redsense System comprises a patented fiber optic sensor designed for use with either a venous needle or central venous catheter, linked to an alarm unit. The system has been developed with a strong focus on meeting the stringent safety requirements of healthcare providers in the dialysis sector. Alarmingly, globally, 21 individuals lose their lives each week due to blood leakage during hemodialysis, making this technology a critical advancement in patient care. One major development for Redsense Medical is its recent listing on the OTCQX market under the ticker symbol 'RDSMF.' The United States is a pivotal market for the company, with 99% of its revenue in 2022 generated from the US. The company is actively planning to expand its presence in the US market, providing easier access for US investors to participate in their growth journey. Looking ahead to the remainder of 2023 and 2024, Redsense Medical has ambitious goals, including continued growth in the US market and raising awareness about the importance of monitoring devices in home dialysis. Additionally, the company is set to launch a new product called "The Clamp," which will further enhance patient safety during hemodialysis treatments. Overall, Redsense Medical's dedication to improving patient safety and healthcare outcomes in the field of hemodialysis positions it as a key player in the medical technology industry, and its expansion plans in the US market are poised to make a significant impact. Contact Details Proactive Investors +1 604-688-8158

September 29, 2023 01:39 PM Eastern Daylight Time

Article thumbnail News Release

Spectral AI announces "single largest contract to date"

Spectral AI Inc

Spectral AI Ltd (NASDAQ:MDAI) founder and CEO Wensheng Fan speaks to Thomas Warner from Proactive after the medical-focused artificial intelligence company announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The CEO describes the contract as Spectral AI's "single largest to date" and highlights that it represents an important step forward in its commercial efforts. The deal includes a base phase of $55mln for FDA clearance of "Deep View" in burn indication. The technology aims to assist ER physicians in determining whether burn patients should be transferred to specialized burn centers. With 1.1 million burns occurring in the US annually, the potential for Deep View's application in emergency rooms and trauma centers is vast. Additionally, the technology will play a role in the treatment flow of both burn and diabetic foot ulcers, further expanding its clinical utility. Fan explains that following Spectral's recent move from London's AIM to the NASDAQ, the contract signifies a pivotal moment in the company's history, cementing its commercial future and revealing more about its potential impact on the healthcare sector. Contact Details Proactive Investors +44 20 7989 0813

September 29, 2023 01:17 PM Eastern Daylight Time

Article thumbnail News Release

Accelmed Files Transaction Statement on Schedule 13E-3 with Securities and Exchange Commission


Today Minerva Surgical, Inc. (the “Company”) (Nasdaq: UTRS), entered into a share purchase agreement (the “Purchase Agreement”) for the sale of an aggregate of 97,751,711 shares (the “Shares”) of its common stock (“Common Stock”) in a private placement (the “Private Placement”) by the Company to Accelmed Partners II L.P. (“Accelmed LP”), at an offering price of $0.2046 per share, for aggregate consideration of $20,000,000.07. In connection with a contemplated refinancing by the Company of its Loan and Security Agreement, dated as of October 8, 2021, by and among the Company, the Canadian Imperial Bank of Commerce, and each other person party thereto, as a borrower from time to time, as amended (the “Loan and Security Agreement”, and such refinancing, the “Refinancing”), it is expected that potential lenders shall require as a condition to the Refinancing that the Company complete a equity financing of at least $20,000,000 prior to the Refinancing (the “Lender’s Refinancing Condition”). As of the date hereof, Accelmed LP owns 68.8% of the issued and outstanding shares of Common Stock of the Company, based upon 177,573,152 shares of Common Stock issued and outstanding on September 14, 2023, as reported by the Company in the Purchase Agreement. Upon the closing of the Private Placement, Accelmed LP will own 79.9% of the issued and outstanding shares of Common Stock of the Company, based upon 177,573,152 shares of Common Stock issued and outstanding on September 14, 2023, as reported by the Company in the Purchase Agreement. As the Private Placement may be viewed as a step in a series of transactions, which constitute a “going-private” transaction under Rule 13e-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Accelmed LP, Accelmed Partners II GP L.P., Accelmed Partners II, LLC and Uri Geiger (collectively, the “Filing Persons”) have filed a transaction statement on Schedule 13E-3 (“Transaction Statement”) with the United States Securities and Exchange Commission (the “SEC”). The Filing Persons have previously disclosed that they are considering effecting a transaction pursuant to which (i) the Common Stock may be delisted from trading on the Nasdaq Capital Market (“Nasdaq”); and (ii) the registration of the Common Stock under the Exchange Act would be terminated (a “Take Private Transaction”). In connection with such potential Take Private Transaction, Accelmed LP has previously disclosed that it is evaluating acquiring shares of Common Stock from existing stockholders in one or more privately negotiated transactions and may discuss such privately negotiated transactions with certain existing stockholders of the Company. The Private Placement is not being conducted in conjunction with any Take Private Transaction, but rather to satisfy the Lender’s Refinancing Condition. The closing of the Private Placement is subject to the condition that the terms of the Refinancing are acceptable to Accelmed LP, in its sole and absolute discretion, and other customary closing conditions. The closing of the Private Placement may not take place prior to October 28, 2023. No assurances can be made that the Private Placement will close, that the Refinancing will occur, or that any Take Private Transaction will be consummated. The Company’s stockholders and other investors are urged to read the Transaction Statement and the exhibits to the Transaction Statement carefully because they contain important information about the Private Placement, the Refinancing, any potential Take Private Transaction, and other transactions that may be deemed in furtherance of a “going-private” transaction. The Transaction Statement and the exhibits to the Transaction Statement can be found on the SEC’s website at In addition, copies of these documents can be obtained, without charge, by contacting Accelmed LP at Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. As of the date of this release, the Filing Persons have not entered into definitive agreements to effect a Take Private Transaction. If and when the Filing Persons determine to proceed with a Take Private Transaction and establish the terms thereof, the Transaction Statement will be amended at such time to disclose the terms of such Take Private Transaction, and the Company will file such amendment with the SEC and will prepare and cause to be mailed the amended Transaction Statement to its stockholders as required by law. In addition to receiving the amended Transaction Statement by mail, stockholders will be able to obtain the final Transaction Statement without charge, on the SEC’s website at In addition, copies of these documents can be obtained, without charge, by contacting Accelmed LP at Ugland House, South Church Street PO Box 309, Grand Cayman KY1-1104, Cayman Islands. SECURITYHOLDERS ARE URGED TO READ THESE MATERIALS AND OTHER MATERIAL FILED WITH OR FURNISHED TO THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION. This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should a Take Private Transaction occur. About Accelmed Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies. Since 2009, Accelmed has deployed over half a billion dollars into companies spanning medical devices, diagnostics, digital health and technology-enabled healthcare services. Accelmed seeks to accelerate value and scale innovation across the HealthTech field by bringing to bear the team’s industry experience, operational and financial expertise, and strong global relationships. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements may include, but are not limited to, statements regarding the closing of the Private Placement and the Accelmed LP’s ownership of the Common Stock upon the closing of the Private Placement. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Actual results may differ materially from these statements and from actual or future events due to a variety of factors. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Filing Persons undertake no obligation to update or review any estimate, projection, or forward-looking statement. Contact Details Accelmed Steve Rubin +1 914-364-0284 Company Website

September 29, 2023 11:45 AM Eastern Daylight Time

Article thumbnail News Release

Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium

Voyageur Pharmaceuticals Ltd

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF). Appiah gives an overview of the note and the company itself, explaining that contrast agents containing barium sulphate or iodine are consumed prior to x-rays or CT scans, aiding doctors in visualizing the interior of the body. Voyageur aims to leverage its own facilities and resources to establish an integrated value chain for these agents in North America. The company has already launched its first product in Canada, with plans to expand to the US post-FDA approvals. By 2025, Voyageur intends to source barium from its fully-owned Frances Creek Mine, potentially reducing raw ingredient costs significantly. Appiah explains that Voyageur is currently seeking funding to help support its development. Contact Details Proactive Investors +1 604-688-8158

September 28, 2023 02:02 PM Eastern Daylight Time

Article thumbnail News Release

1606 announces launch of ChatCBD, a revolutionary AI chatbot to enhance customer experiences

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Proactive's Steve Darling with news the company is launching ChatCBD, an AI chatbot designed to revolutionize the customer experience. Lambrecht explained that ChatCBD, a conversational e-commerce tool, is set to debut through a partnership with Cool Blue Distribution. This strategic collaboration will enable 1606 to integrate its proprietary AI merchandizing ChatBot into Cool Blue's website. ChatCBD has been custom-tailored to provide comprehensive responses to customer inquiries related to CBD and offer product recommendations from the range of retail brands available through Cool Blue Distribution, a leading CBD distributor in the United States. The chatbot's standout feature lies in its utilization of Natural Language Processing (NLP) technology, which equips it with the capability to comprehend and respond to customer queries with a high degree of precision and understanding, akin to human interactions. Furthermore, ChatCBD operates 24/7, ensuring that customers receive assistance and solutions to their questions promptly, even beyond regular business hours. This innovative approach not only enhances the customer experience but also showcases 1606 Corp's commitment to leveraging cutting-edge technology to provide valuable solutions in the growing CBD market. By offering an AI-driven chatbot for CBD-related inquiries and product recommendations, 1606 Corp aims to create a seamless and informative shopping experience for consumers exploring the world of CBD products. Contact Details Proactive Canada +1 604-688-8158

September 28, 2023 01:46 PM Eastern Daylight Time

Article thumbnail News Release

Joshua Borders Appointed as CEO of AmeriLife’s Senior Market Advisors


Senior Market Advisors (SMA), a fast-growing field marketing organization (FMO) in the health insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), today announced the appointment of Joshua Borders to principal and chief executive officer. Borders, who succeeds SMA founder Jeff Pitta, was previously founder and managing partner of Buffalo Health Advisors, a Nashville-based insurance distributor and downline affiliate of SMA that specializes in Medicare Advantage, Medicare Supplement, PDP solutions, and health insurance for the under-65 market. At Buffalo, Borders oversaw a nationwide network of more than 500 field agents and grew the business 20% year-over-year for nine straight years, establishing the company as a top MAPD distributor in the state. Borders began his career as an independent sales agent focused on the Medicare Advantage market, bringing with him a client-centered approach and relentless focus on empowering agents with the tools and resources they need for success. “I’m grateful for the opportunity to lead SMA alongside an amazing team and our partners at AmeriLife,” said Borders. “SMA’s story is one of continued success, thanks in large part to an approach that isn’t content being just any FMO. SMA has – and will continue to be – a true difference-maker in the lives of the agents we help, the clients they serve, and the communities we support.” Founded in 2007, SMA boasts over 9,000 agents across 49 states, providing them with access to top Medicare and health insurance contracts, as well as life insurance and other products to help them serve the senior market. SMA is highly regarded for its best-in-class training, expert marketing support, and robust technology platforms that are designed by and for agents to better manage and grow their books of business, and support and scale growing independent marketing organizations (IMOs). SMA became an affiliate of AmeriLife in 2021. SMA is also deeply committed to putting people over profits. Since its founding, SMA has pledged more than $10 million to charities and community organizations locally and around the world, including to organizations such as Feeding America, King’s Kids Africa, and global nonprofit charity: water. “SMA has written the playbook on what it takes to be a successful FMO,” said Robert “Bobby” Bache, vice president of Life and Health Distribution for AmeriLife Health. “I’m grateful for Josh’s partnership and confident that, under his direction, SMA will continue to raise the bar in our industry.” “I want to thank Jeff for his many years of service at SMA and congratulate Josh on his new role,” added Scotty Elliot, Chief Distribution Officer for AmeriLife Health. “Josh’s appointment is a testament to his leadership, business acumen, and agent-first mindset. I believe he’s the perfect choice to lead SMA, and I couldn’t be more excited for the road ahead.” ### About Senior Market Advisors Senior Market Advisors (SMA) has been putting people over profits since 2007, through hard work and a commitment to “doing right” by the consumer. We know the grit and determination involved in becoming a career agent. And as a result, we have become one of the fastest growing FMOs, doubling our business each year for the past five years. For more information, visit us online at About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 Partnership Inquiries Patrick Nichols +1 727-726-0726 Company Website

September 28, 2023 01:00 PM Eastern Daylight Time

Article thumbnail News Release

Avingtrans in a strong cash position after "beating city expectations again"

Avingtrans PLC

Avingtrans (LON:AVG) CEO Steve McQuillan and CFO, Stephen King speak to Thomas Warner from Proactive London after the engineering company released its preliminary results for the year to 31 May 2023. McQuillan gives a brief overview of the company's unique way of doing business, which combines engineering with elements of the private equity model. He highlights that Avingtrans specialises in serving highly regulated markets such as nuclear, defence, aerospace, and medical. Their business approach, termed "Pinpoint, Invest, Exit," involves identifying struggling engineering businesses, acquiring them, revamping their operations, and subsequently selling them. King reports a revenue increase of 17.5% for the year ending May 31, 2023, which he suggests "beat city expectations again". The company also held £13 million in cash reserves at the end of the period, enabling it to undertake potential future acquisitions and investments. McQuillan says he was pleased with the resilience of the business during a year blighted by challenging conditions in the market. He also adds that the market is undervaluing the medical side of the business. Looking to the future, he suggests its more likely that Avingtrans will be divesting businesses over the next few years rather than acquiring any major new ones, not least because its still "digesting" two relatively recent acquisitions. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813

September 28, 2023 09:30 AM Eastern Daylight Time

Article thumbnail News Release

Tune Insight secures $3.4m as it pushes the boundaries from a data economy to a secure insight economy

Tune Insight

Despite the ever increasing data-dependance for all critical business decisions and the never ending need of data to feed machine learning, companies are prevented from collaborating on and valorizing sensitive data because of cyber risks, fear of losing competitive edge and regulatory constraints. Helping organizations to overcome this hurdle, Tune Insight is today announcing a $3.4m funding round as it helps them automate collective intelligence extraction, reduce data liability, streamline compliance, while re-enforcing data security and privacy. The oversubscribed seed funding round was led by 14Peaks Capital with participation of US-based, Debiopharm and Zurich Cantonal Bank. Existing investors Wingman Ventures also participated in the funding round. Tune Insight was founded in 2021 by Juan R. Troncoso Pastoriza, Frederic Pont, Romain Bouyé and Jean-Pierre Hubaux. The startup is a confidential collaborative analytics and privacy-preserving machine learning solution. The genesis of Tune Insight lies in 2016, when Swiss hospitals came to the founders (then researchers) at the Swiss Federal Institute of Technology (EPFL) asking if the latest progress in applied cryptography could help solve a challenge they could not overcome, but paramount for personalized healthcare: hospitals wanted to collaborate with each other, but without transferring or revealing their patient data to others. Today, Tune Insight is deployed at University Hospital Zurich, CHUV in Lausanne, Inselspital in Bern, Switzerland, and powers applications such as survival analysis for precision oncology and personalized reference ranges. The latter application enables practitioners to rely on up-to-date reference ranges for their patients, based on collective data of 9 million data points from over 250,000 patients, instead of outdated ranges from a less relevant population. For University Spital Basel, Tune Insight enables the secure training of dermatology machine learning models on skin images across jurisdictions. Tune Insight solutions also bridge the trust gap between payers like Groupe Mutuel with care providers for value-based healthcare (VBHC), and pharmaceutical companies with hospitals for streamlined access to real-word evidence (RWE). In other domains, Tune Insight’s solutions are used by actuaries to facilitate collective risk computations for insurances and in financial services for collective fraud detection, anti-money laundering (AML) and combating financing of terrorism. In cybersecurity, Tune Insight works with managed security service providers (MSSPs) and Armassuisse, the procurement branch of the Swiss military, enabling collective cyber resilience to better defend against cyber attacks. The confidential computing operations supported by the Tune Insight platform range from private set intersection to advanced data analytics to secure federated learning on structured data, including images, which play an increasing role in healthcare and for predictive maintenance. Tune Insight is also working at extending support for privacy-preserving generative AI. Starting from secure data collaborations and privacy-preserving federated learning, Tune Insight is accompanying its customers towards data and model valorization. Juan R. Troncoso Pastoriza, co-founder & CEO of Tune Insight, has been working on privacy-enhancing technologies since 2005 commented: “The data economy falls short of its promise for very valuable, highly confidential or regulated data. In a data-driven world, protecting data not only at rest and in transit, but also in-use, is paramount. Combined with the increasing need for organizations to work together with others, both for collaborations and valorization, and progress towards more protections for citizens and customer data through regulations like GDPR, robust applied cryptography solutions that combine the best privacy-enhancing technologies are of greatest importance in all domains. At Tune Insight, our vision is to transform the paradigm of the data economy into an insight economy that better protects sensitive data, that is more secure, fair, and protective of privacy and confidentiality rights”. Tune Insight will deploy this funding round to strengthen its position for confidential collaborative analytics and machine learning in healthcare, financial services and cybersecurity, strengthen sales and marketing teams, and accelerate international expansion in Europe and the US. Edoardo Ermotti, Founder and Managing Partner of 14Peaks Capital, commented: “Tune Insight stands at the forefront of addressing a critical gap in the realm of confidential collaborative analytics. Their software, situated at the intersection of AI/ML, SaaS, and data security, offers compelling applications across industries, including financial services. This aligns seamlessly with the core values and strategic focus we have at 14Peaks Capital. We are excited about this partnership and look forward to contributing to Tune Insight's next phase of growth, continuing to revolutionize enterprise collaboration on sensitive and regulated data while mitigating the customary associated risks.” Alexander Lange, Founding Partner at remarked: “We believe that AI's bottlenecks won't be software development, tooling or algorithms but access to raw compute and high quality data sets. Tune Insight is making a breakthrough contribution to the latter by building an operating system for model training on confidential data without leakage. For the first time, adversarial stakeholders operating across multiple levels of a given value chain are economically motivated to collaborate. This will lead to significant efficiency gains and better products for their customers.” Pascal Mathis, Founding Partner, Wingman Ventures, added: “Tune Insight is the poster child of a Swiss startup on its way to global success: born on deep technology from the Swiss Federal Institute of Technology, with a complementary team of experienced international co-founders, supported by the Swiss startup ecosystem, and signing as first customers Swiss companies that are world leaders in healthcare and financial services. Tune Insight is now ready to build on those early successes to accelerate towards becoming a global leader in secure collective data analytics and machine learning across industries. At Wingman, we are proud to have been Tune Insight’s first investor at pre-seed.” About Tune Insight Tune Insight provides confidential collaborative analytics and federated machine learning B2B solutions in healthcare, cybersecurity, financial services and beyond. Our vision is to transform the upcoming paradigm of the data economy into an insight economy that better protects the data, that is more secure, fair, and protective of privacy and confidentiality rights. About 14Peaks Capital 14Peaks is an early-stage investor in B2B SaaS companies located in Europe and the US. Within SaaS, they invest across three core verticals; Fintech, Proptech, and Future of Work. They initially partner with founders from pre-seed to Series A and support them throughout their growth journey by providing capital, operational support, network access and strategic advice. About Inflection is a global venture platform led by seasoned investors and entrepreneurs based in Boston, USA. The firm is pioneering the frontiers of computation by providing capital, networks and insights to outlier entrepreneurs. About Wingman Ventures Wingman Ventures is Switzerland’s leading pre-seed fund, backing founder teams building tech companies with the potential to become global market leaders. Wingman has a track record of supporting exceptional founders in creating breakthrough companies and has the passionate conviction that the Swiss startup ecosystem is just starting to write its best success stories. About Debiopharm Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017 Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As of September 2023, Debiopharm Innovation fund is expanding its footprint through a new Seed financing activity. About Zurich Cantonal Bank Zürcher Kantonalbank is an independent public-law institution of the Canton of Zurich, incorporated under the laws of the Canton of Zürich. Its registered corporate domicile and principal place of business is in Zurich, Switzerland. It has received top ratings from the rating agencies Standard & Poor’s, Moody’s and Fitch (AAA/Aaa). With more than 5,000 employees, Zürcher Kantonalbank offers its clients a comprehensive range of products and services. The bank’s core activities include financing businesses, asset and wealth management, trading, capital market transactions, deposits, payment transactions and card business. Zürcher Kantonalbank provides clients and distribution partners with a comprehensive range of investment and retirement provision products and services. Contact Details Tune Insight Bilal Mahmood +44 7714 007257 Company Website

September 28, 2023 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Federal Publications Seminars (FPS) Embraces Industry Standardization with Adoption of CMS™ and CMBOK®

National Contract Management Association

Federal Publications Seminars (FPS), a leading government contract training provider, has announced a significant milestone in its commitment to advancing the contract management profession. FPS proudly embraces the National Contract Management Association's (NCMA) ANSI Approved Contract Management Standard™ (CMS™) and the Contract Management Body of Knowledge (CMBOK®) as the cornerstone for hiring, career development, and training of contract management professionals. The CMS™, recognized as the standard global language of government contracting, and the comprehensive CMBOK® collectively offer a unified framework to define, discuss, and advance contract management phases, domains, competencies, and skills. “Our adoption of these standards reaffirms FPS’s support of NCMA and dedication to cultivating excellence and promoting a common language within the contract management community,” said Andy King, President of FPS. Mr. King stated, "By aligning our training courses with the adoption of CMS™ and CMBOK®, we are poised to provide even greater support to our thriving FPS education community. Our partnership and collaboration with the National Contract Management Association (NCMA) reinforces our commitment to cultivating a more robust, knowledgeable, and ethical federal government contracting industry." “Through this collaboration, FPS aims to empower its clients to not only meet compliance requirements but also gain a competitive edge by harnessing their newfound expertise. The synergy between FPS and NCMA promises a brighter future for professionals in the federal contracting arena,” Mr. King concluded. "We appreciate Federal Publications Seminar's commitment to advancing the contract management profession through the adoption of the CMS™ and CMBOK®. they join leading organizations on our journey toward common language to foster global excellence," stated Kraig Conrad, Chief Executive Officer of NCMA. This move aligns FPS with the Department of Defense, civilian agencies of the U.S. government, industry leaders, and higher education institutions that have also embraced the CMS™ for their hiring, training, and educational programs. FPS's commitment to these standards is not only a testament to its leadership in the profession, but also an expression of support for NCMA's pivotal role in advancing the profession. For more information on NCMA's Common Language Adoption, please visit: The National Contract Management Association (NCMA), which was founded in 1959 and is the world’s leading association in the field of contract management. The organization, which has over 18,000 members, is dedicated to the professional growth and educational advancement of procurement and acquisition personnel worldwide. NCMA strives to serve and inform the profession and industry it represents and to offer opportunities for the open exchange of ideas in neutral forums. To find out more, please visit About Federal Publication Seminars: Federal Publications Seminars (FPS) has been the leading provider of government contracts training and education for more than 60 years. FPS offers hundreds of in-person and online courses designed to provide in-house counsel, procurement officers, contract administrators, and accounting professionals and firms with solid, comprehensive opportunities to stay current on critical issues throughout the government contracting market. FPS instructors are nationally recognized leaders in the government contracting industry. For more information or to subscribe, visit or call 888.494.3696. Follow FPS on social channels for the latest updates, class notifications and promotions @fedpubseminars. Contact Details National Contract Management Association Holly Dehesa +1 281-865-3296 Company Website

September 28, 2023 06:55 AM Eastern Daylight Time

12345 ... 217